LORVIQUA® (lorlatinib) as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.1
LORVIQUA® (lorlatinib) as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC whose disease has progressed after:
A third generation ALK TKI, LORVIQUA® is designed to address the unmet medical needs of CNS progression and ALK resistance mutations2,3,4 and has demonstrated efficacy in both treatment-naïve patients and those whose disease had progressed on a previous ALK TKI.1,2,5
As a 2nd line therapy LORVIQUA® has a generally manageable safety profile, with a low permanent discontinuation rate (3.4%) due to treatment-related AEs* and a once-daily dosing schedule, taken with or without food.1,7
AE: Adverse Event, ALK: Anaplastic Lymphoma Kinase, CNS: Central Nervous System, NSCLC: Non-Small Cell Lung Cancer, TKI: Tyrosine-Kinase Inhibitor.
*In the phase II portion of the Phase I/II registrational study (n=295), 3.4% of patients discontinued treatment due to a treatment-related adverse event.1,7
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024